Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 14/20 | 0.97 |
| ▸ | LPAR1 | Q92633 | 13/20 | 0.97 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.69 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.67 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.54 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2732573 | 1.00 | LPAR3 (0.97) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31198159 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2813163 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL30443866 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL2814732 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL10896195 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL31439420 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL496845 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL5055004 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 | |
| SCHEMBL29458233 | 0.98 | LPAR3 (1.00) | LPAR3LPAR1LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011034397-A2 | METHOD FOR PREDICTING DRUG TARGETS AND SCREENING FOR DRUGS FOR PATHOGENIC MICROORGANISMS USING ESSENTIAL METABOLITES | 한국과학기술원 (KR) | 2011-03-24 | — | — | WO | claimed |
| US-7628977-B2 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-12-08 | — | — | US | claimed |
| US-20080253971-A9 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-16 | — | — | US | claimed |
| EP-0935139-B1 | IMMUNOHISTOCHEMICAL STAINING COMPOSITION | DAIICHI PURE CHEMICALS CO LTD (JP) | 2004-11-17 | — | — | EP | claimed |
| EP-1444991-A1 | Novel targeted compositions for diagnostic and therapeutic use | IMARX PHARMACEUTICAL CORP. (US) | 2004-08-11 | — | — | EP | claimed |
| US-20040062718-A1 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-04-01 | — | — | US | claimed |
| US-20020052310-A1 | Particles for inhalation having sustained release properties | MASSACHUSETTS INSTITUTE OF TECHNOLOGY THE PENN STATE RESEARCH FOUNDATION | 2002-05-02 | — | — | US | claimed |
| US-20020028474-A1 | Composition for immunohistochemical staining | DAIICHI PURE CHEMICAL CO., LTD. (JP) | 2002-03-07 | — | — | US | claimed |
| EP-0674646-B1 | LIPID DERIVATIVES OF PHOSPHONOACIDS FOR LIPOSOMAL INCORPORATION AND METHOD OF USE | CHIMERIX INC (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0831932-A4 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0935139-A1 | IMMUNOHISTOCHEMICAL STAINING COMPOSITION | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 1999-08-11 | — | — | EP | claimed |
| WO-1998024425-A1 | CISPLATINUM COMPRISING PHARMACEUTICAL | RIJKSUNIVERSITEIT UTRECHT (NL) | 1998-06-11 | — | — | WO | claimed |
| EP-0831932-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040285-A1 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX PHARMACEUTICAL CORP. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0119056-B1 | SURFACTANT COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME FOR USE IN THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME | TOKYO TANABE COMPANY LIMITED (JP) | 1990-08-29 | — | — | EP | claimed |
| US-4603124-A | FILM-FORMING MIXTURE OF CHOLINE PHOSPHO GLYCERIDE, ACID PHOSPHOLIPID, FATTY ACID, AND LIPOPROTEIN | TOKYO TANABE COMPANY, LIMITED (JP) | 1986-07-29 | — | — | US | claimed |
| JP-59164724-A | — | — | None | — | — | JP | disclosed |
| JP-61065821-A | — | — | None | — | — | JP | disclosed |
| JP-S59164724-A | SURFACTANT AND REMEDY FOR RESPIRATORY DISTRESS SYNDROME CONTAINING THE SAME | TOKYO TANABE CO LTD | 1984-09-17 | — | — | JP | disclosed |
| JP-S06165821-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080253971-A9 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR3 88/4885LPAR1 112/4885LPAR2 89/4885 |
| US-20040062718-A1 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR3 88/4885LPAR1 112/4885LPAR2 89/4885 |
| US-20020052310-A1 | Particles for inhalation having sustained release properties | SMPD4, SMPD2, SMPD3 | LPAR3 88/4885LPAR1 112/4885LPAR2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.